NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of ...

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in ...

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.

RNA-based vaccines, which instruct cells to produce proteins that can prevent or treat disease, show great promise in ...

Shares in the company are trading nearly 54% down compared to pandemic-high prices. Image credit: Shutterstock/ ShU studio.